Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-22T08:04:12.632Z Has data issue: false hasContentIssue false
  • English
  • Français

Creatine Phosphokinase and Psychiatric Illness

Published online by Cambridge University Press:  29 January 2018

Lynn A. Cunningham ,
Charles L. Rich ,
Robert A. Woodruff Jr.  and
John W. Olney
Lynn A. Cunningham
Affiliation:
Washington University School of Medicine, St Louis, Missouri 63110, U.S.A
Charles L. Rich
Affiliation:
Washington University School of Medicine, St Louis, Missouri 63110, U.S.A
Robert A. Woodruff Jr.
Affiliation:
Washington University School of Medicine, St Louis, Missouri 63110, U.S.A
John W. Olney
Affiliation:
Washington University School of Medicine, St Louis, Missouri 63110, U.S.A
Get access Rights & Permissions [Opens in a new window]

Extract

Since Schiavone and Kaldor (16) reported the incidental finding of increased creatine Phosphokinase (CPK) in patients with schizophrenia a number of studies of the enzyme have appeared in the literature. Bengzon et al. (2), reported among a group of 30 schizophrenics, CPK elevations, which returned to normal during the course of treatment with phenothiazines. These authors investigated a second group of 60 untreated patients who were ‘acutely psychotic’ and found abnormally high CPK levels in half of them. However no mention was made of diagnostic criteria, nor of attempts to control for extraneous circumstances known to elevate the enzyme.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 124 , Issue 578 , January 1974 , pp. 87 - 91
Copyright
Copyright © Royal College of Psychiatrists, 1974 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

∗.

This work was supported in part by U.S.P.H.S. grants MH-19972, 13002, 09247, 05804, and by NS-09156.

A synopsis of this paper was published in the April 1973 Journal.

References

1. Belton, N., Backus, R., and Millichap, J. (1967). ‘Serum creatine Phosphokinase activity in epilepsy.’ Neurology, 17, 1073–6.Google Scholar
2. Benozon, A., Hippius, H., and Kanig, K. (1966). ‘Some changes in the serum during treatment with psychotropic drugs.’ Journal of Nervous and Mental Diseases, 143, 369–76.Google Scholar
3. Goodley, E. (1968). ‘Evaluations of enzyme diagnosis in myocardial infarction.’ American Journal of the Medical Sciences, 256, 300–5.Google Scholar
4. Crowley, L. (1968). ‘Creatine Phosphokinase activity of myocardial infarction, heart failure and following various diagnostic and therapeutic procedures.’ Clinical Chemistry, 14, 1185–96.CrossRefGoogle ScholarPubMed
5. Eschar, J., and Zimmerman, H. (1967). ‘Creatine Phosphokinase in disease.’ American Journal of the Medical Sciences, 48, 272–82.Google Scholar
6. Feighner, J., Robins, E., Guze, S., et al (1972). ‘Diagnostic criteria for use in psychiatric research.’ Archives of General Psychiatry, 26, 57–63.CrossRefGoogle ScholarPubMed
7. Meltzer, H. (1968). ‘Creatine kinase and aldolase in serum: Abnormality common to acute psychosis.’ Science, 159, 1368–70.CrossRefGoogle Scholar
8. Meltzer, H. (1969). ‘Muscle enzyme release in the acute psychosis.’ Archives of General Psychiatry, 21, 102–12.Google Scholar
9. Meltzer, H. (1969). ‘Intramuscular chlorpromazine and creatine kinase: Acute psychosis or local muscle trauma? (Technical Comment.)’ Science, 164, 727–8.CrossRefGoogle ScholarPubMed
10. Meltzer, H., Elkum, L., and Moline, R. (1969). ‘Serum enzyme changes in newly admitted psychiatric patients. Part I.’ Archives of General Psychiatry, 21, 731–8.CrossRefGoogle Scholar
11. Meltzer, H., and Moline, R. (1970). ‘Muscle abnormalities in acute psychosis.’ Archives of General Psychiatry, 23, 481–91.Google Scholar
12. Meltzer, H., Mrozak, S., and Boyer, M. (1970). ‘Effect o intramuscular injections on serum creatine Phosphokinase activity.’ American Journal of the Medical Sciences, 259, 42–8.Google Scholar
13. Meltzer, H., Nankin, R., and Raferty, J. (1971). ‘Serum creatine Phosphokinase activity in newly admitted psychiatric patients. Part II.’ Archives of General Psychiatry, 24, 568–72.CrossRefGoogle Scholar
14. Nygren, A. (1966). ‘Serum creatine Phosphokinase activity in chronic alcoholism in connection with acute alcohol intoxication.’ Acta Medica Scandinavica, 179, 623–30.Google Scholar
15. Perkofp, G., Dioso, M., Bleisch, V., et al. (1967). ‘A spectrum of myopathy associated with alcoholism.’ Annals of Internal Medicine, 67, 481–92.Google Scholar
16. Schiavone, D., and Kaldor, J. (1965). ‘Creatine Phosphokinase levels and cerebral disease.’ Medical Journal of Australia, 2, 790–2.CrossRefGoogle ScholarPubMed
17. Schweid, D., Steinberg, J., and Sudak, H. (1972). ‘Creatine Phosphokinase and psychosis.’ Archives of General Psychiatry, 26, 263–5.Google Scholar
18. Song, S., and Rubin, E. (1972). ‘Ethanol produces muscle damage in human volunteers.’ Science, 175, 327–8.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.